Multicenter, open-label parallel-groups study comparing tocilizumab versus conventional treatment in rheumatoid arthritis with the complication of AA amyloidosis
Not Applicable
Recruiting
- Conditions
- rheumatoid arthritis
- Registration Number
- JPRN-UMIN000002421
- Lead Sponsor
- AA amyloidosis clinical research conference
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. Pregnancy, lactation or planning pregnancy 2. Complicating severe infection 3. History of hypersensitivity to the treatment drug 4. Patients who are judged to be inappropriate by investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of the amyloid deposition in the gastric biopsy specimen
- Secondary Outcome Measures
Name Time Method Change of renal function Serum creatinine, urinary protein, urinary creatinine, estimated creatinine clearance, cystatin C Change of serum SAA Change of diarrhea frequency Change of DAS28-ESR